Stock Track | Moderna, Inc. Soars 5.01% Intraday on $54.3 Million Funding for Bird Flu Vaccine

Stock Track12-19

Moderna, Inc. (MRNA) saw its stock surge 5.01% during intraday trading on Thursday, driven by positive investor sentiment following the announcement of significant funding for its bird flu vaccine development.

The U.S. drugmaker secured up to $54.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to support late-stage development of its experimental mRNA-based bird flu vaccine, mRNA-1018. The Phase 3 trial is expected to begin in early 2026 in the UK and the U.S., building on earlier studies showing strong immune responses. Moderna also committed to reserving 20% of its production capacity for low- and middle-income countries at affordable prices in case of a pandemic.

The funding highlights the potential of mRNA technology to accelerate vaccine development, as it can be designed and produced much faster than traditional methods. This development aligns with Moderna's broader strategy to respond to pandemic threats within 100 days of identification.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130429174?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 00:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130429174","market":"hk","top_or_hot":-1,"title":"Stock Track | Moderna, Inc. Soars 5.01% Intraday on $54.3 Million Funding for Bird Flu Vaccine","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) saw its stock surge 5.01% during intraday trading on Thursday, driven by positive investor sentiment following the announcement of significant funding for its bird flu vaccine development.</p><p>The U.S. drugmaker secured up to $54.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to support late-stage development of its experimental mRNA-based bird flu vaccine, mRNA-1018. The Phase 3 trial is expected to begin in early 2026 in the UK and the U.S., building on earlier studies showing strong immune responses. Moderna also committed to reserving 20% of its production capacity for low- and middle-income countries at affordable prices in case of a pandemic.</p><p>The funding highlights the potential of mRNA technology to accelerate vaccine development, as it can be designed and produced much faster than traditional methods. This development aligns with Moderna's broader strategy to respond to pandemic threats within 100 days of identification.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna, Inc. Soars 5.01% Intraday on $54.3 Million Funding for Bird Flu Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna, Inc. Soars 5.01% Intraday on $54.3 Million Funding for Bird Flu Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-12-19 00:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) saw its stock surge 5.01% during intraday trading on Thursday, driven by positive investor sentiment following the announcement of significant funding for its bird flu vaccine development.</p><p>The U.S. drugmaker secured up to $54.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to support late-stage development of its experimental mRNA-based bird flu vaccine, mRNA-1018. The Phase 3 trial is expected to begin in early 2026 in the UK and the U.S., building on earlier studies showing strong immune responses. Moderna also committed to reserving 20% of its production capacity for low- and middle-income countries at affordable prices in case of a pandemic.</p><p>The funding highlights the potential of mRNA technology to accelerate vaccine development, as it can be designed and produced much faster than traditional methods. This development aligns with Moderna's broader strategy to respond to pandemic threats within 100 days of identification.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1130429174","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130429174","pubTimestamp":1766076649,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (MRNA) saw its stock surge 5.01% during intraday trading on Thursday, driven by positive investor sentiment following the announcement of significant funding for its bird flu vaccine...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股追踪|Moderna，Inc.盘中大涨5.01%获5430万美元融资用于禽流感疫苗","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) saw its stock surge 5.01% during intraday trading on Thursday, driven by positive investor sentiment following the announcement of significant funding for its bird flu vaccine development.The U.S. drugmaker secured up to $54.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to support late-stage development of its experimental mRNA-based bird flu vaccine, mRNA-1018. The Phase 3 trial is expected to begin in early 2026 in the UK and the U.S., building on earlier studies showing strong immune responses. Moderna also committed to reserving 20% of its production capacity for low- and middle-income countries at affordable prices in case of a pandemic.The funding highlights the potential of mRNA technology to accelerate vaccine development, as it can be designed and produced much faster than traditional methods. This development aligns with Moderna's broader strategy to respond to pandemic threats within 100 days of identification.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130429174","isCrawlerRequest":true}